No need to file injunction until the FDA approve the ANDA. The generics will not launch until that time so no need to waste the money. JT said they would file when needed.
But, no doubt that I strongly agree with you on sell EU with CVR US mkt based on appeal.
Put the company out on the market and get the highest bidder for EU (NVS, PPE, AZN, GSK) and maybe we can get out of this.